contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


lipum-ab-interim-report-q3-for-the-period-july-september-2024

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Lipum is a biopharmaceutical company. The company is in the clinical phase and specializes in the discovery and development of new treatments for chronic inflammatory diseases. The company's drug candidate is based on an antibody intended to be used in treatments to block a specific molecule in the immune system. The drug candidate is in the clinical phase with preclinical data for rheumatism. The company is also evaluating other inflammatory diseases. Lipum has its operations in Umeå.

Lipum

Lipum AB (publ) has published the interim report Q3 for the period July-September 2024. Below is a summary, a complete report (only in Swedish) is available on the company's website.CEO Ola ...

<div class="mfn-preamble"><p><strong>Lipum AB (publ) has published the interim report Q3 for the period July-September 2024. Below is a summary, a complete report (only in Swedish) is available on the company's website.</strong></p></div><div class="mfn-body"><p>CEO Ola Sandborgh comments: “Time flies and suddenly autumn is here. But as you know, time flies when you have a lot to do and at the same time having fun. Because that's how it is working at Lipum, days are full of activity and goal after goal is achieved. What feels most stimulating and exciting today is that we are approaching the end of the clinical phase 1 study when the last patient has been recruited and only a 90-day follow-up period remains before we can break the code and initiate the final report. With that, we will be able to take part of all the results, which will be in the beginning of 2025 when all analyses and compilations have been completed”</p><p>Financial summary July – September 2024</p><ul><li>Other operating income: KSEK 109 (51)</li><li>Result after financial items: KSEK -1 680 (-6 605)</li><li>Cash and cash equivalents as of September 30: KSEK 12 873 (17 551)</li></ul><p>Significant events during the period July – September 2024</p><ul><li>Lipum AB (publ) recruits Peter Hovstadius as the new Chief Medical Officer (CMO).</li><li>Lipum reports that the last patient has been enrolled in the ongoing phase 1 study with SOL-116.</li><li>Lipum has received a preliminary report regarding the audit of the Horizon 2020 project.</li></ul><p>Significant events after the period</p><ul><li>No significant events to report.</li></ul><p>CEO Ola Sandborgh comments on the report in a live webcast on October 25 at 10:00 LINK.</p><p>The complete report (only in Swedish) is available at&nbsp;<a rel="noopener" href="https://lipum.se/eng/financial-reports/">www.lipum.se</a>.</p></div><div class="mfn-footer mfn-contacts mfn-3e7c58a90e0f"><p><strong class="mfn-heading-1">Contacts</strong><br>Ola Sandborgh, CEO<br><a rel="noopener" href="mailto:ola.sandborgh@lipum.se">ola.sandborgh@lipum.se</a><br>+46 72 218 80 21<br>Web: <a rel="noopener" href="http://www.lipum.se">www.lipum.se</a></p></div><div class="mfn-footer mfn-about mfn-6ab0b4f78e1d"><p><strong class="mfn-heading-1">About Us</strong><br>Lipum AB (publ) is a clinical stage biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in clinical stage supported by solid data for rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum’s unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is&nbsp;G&amp;W Fondkommission.</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/596109ee-d111-4719-9e6c-4d666038abd8/lipum-ab-kvartalsrapport-juli-september-2024.pdf" class="mfn-primary">Lipum AB Kvartalsrapport Juli September 2024</a></p></div>